Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PHVS
stocks logo

PHVS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.613
-4.18%
--
--
-0.641
-24.61%
--
--
-0.664
-20.02%
Estimates Revision
Stock Price
Go Up
up Image
+20.13%
In Past 3 Month
Wall Street analysts forecast PHVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHVS is 36.86 USD with a low forecast of 27.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast PHVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHVS is 36.86 USD with a low forecast of 27.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.690
sliders
Low
27.00
Averages
36.86
High
60.00
Current: 27.690
sliders
Low
27.00
Averages
36.86
High
60.00
Leerink
Leerink
Outperform
upgrade
$28 -> $38
2025-12-03
New
Reason
Leerink
Leerink
Price Target
$28 -> $38
2025-12-03
New
upgrade
Outperform
Reason
Leerink raised the firm's price target on Pharvaris to $38 from $28 and keeps an Outperform rating on the shares following the disclosure of the company's positive topline data from the RAPIDe-3 study. This morning, Pharvaris reported overwhelmingly positive results from the Phase 3 RAPIDe-3 study, which explored deucrictibant, an oral small-molecule antagonist of the bradykinin B2 receptor, as an on-demand treatment for hereditary angioedema attacks. The firm thought shares would have moved higher on the outcome, as it views the data as very strong, combined with the validated market opportunity, as demonstrated by the strength in the Ekterly launch. This may be because investors focus primarily on the primary endpoint magnitude, although, Leerink believes that this is just one point of potential differentiation. The firm further thinks the HAE market is large enough for multiple players, especially as it continues to expand with the approval of new options.
Morgan Stanley
Maxwell Skor
Overweight
maintain
$37 -> $41
2025-12-03
New
Reason
Morgan Stanley
Maxwell Skor
Price Target
$37 -> $41
2025-12-03
New
maintain
Overweight
Reason
Morgan Stanley analyst Maxwell Skor raised the firm's price target on Pharvaris to $41 from $37 and keeps an Overweight rating on the shares. With RAPIDe-3, the firm sees confirmation of a differentiated, rapid, and durable oral on-demand profile. The firm added that it expects investor focus to shift now to the planned NDA submission in 1H26 and the pivotal prophylactic data readout expected in 2H26.
BofA
Neutral
maintain
$27 -> $30
2025-12-03
New
Reason
BofA
Price Target
$27 -> $30
2025-12-03
New
maintain
Neutral
Reason
BofA raised the firm's price target on Pharvaris to $30 from $27 and keeps a Neutral rating on the shares. The company reported positive topline results for the Phase 3 RAPIDe-3 study, with the study meeting its primary endpoint, the analyst tells investors in a research note. The firm thinks additional upside will likely be contingent on positive phase 3 results for decuri' XR in prophylactic HAE.
Morgan Stanley
Overweight
maintain
$34 -> $37
2025-11-13
Reason
Morgan Stanley
Price Target
$34 -> $37
2025-11-13
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Pharvaris to $37 from $34 and keeps an Overweight rating on the shares. The company continues to anticipate topline data from the pivotal Phase RAPIDe-3 trial of deucrictibant for the on-demand treatment of hereditary angioedema attacks in Q4, which represents a meaningful near-term catalyst, the analyst tells investors in a research note.
H.C. Wainwright
NULL
to
Buy
initiated
$60
2025-10-15
Reason
H.C. Wainwright
Price Target
$60
2025-10-15
initiated
NULL
to
Buy
Reason
H.C. Wainwright initiated coverage of Pharvaris with a Buy rating and $60 price target. The company's lead asset deucrictibant is the only oral bradykinin B2 receptor antagonist in development across both on-demand and prophylaxis settings, the analyst tells investors in a research note. The firm says deucrictibant is positioned to set a new standard in hereditary angioedema on-demand and prophylaxis.
Citizens JMP
Outperform
to
NULL
downgrade
$55 -> $52
2025-08-13
Reason
Citizens JMP
Price Target
$55 -> $52
2025-08-13
downgrade
Outperform
to
NULL
Reason
Citizens JMP lowered the firm's price target on Pharvaris to $52 from $55 and keeps an Outperform rating on the shares. Pharvaris continues to execute on its pivotal hereditary angioedema programs with data from its pivotal RAPIDe-3 trial in acute HAE in Q4 and CHAPTER-3 data in HAE prophylaxis in the second half of 2026, the analyst tells investors in a research note. The firm is impressed with management's execution with the first Phase 3 data for deucrictibant for on-demand HAE treatment expected next quarter.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pharvaris NV (PHVS.O) is -9.10, compared to its 5-year average forward P/E of -6.89. For a more detailed relative valuation and DCF analysis to assess Pharvaris NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.89
Current PE
-9.10
Overvalued PE
-4.36
Undervalued PE
-9.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.51
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.63
Undervalued EV/EBITDA
-7.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PHVS News & Events

Events Timeline

(ET)
2025-12-03
16:20:00
Major US Indices Close Higher as Markets Price in Fed Rate Cut This Month
select
2025-12-03
12:30:00
Dow Jones and S&P 500 Rise as Markets Price in Fed Rate Cut This Month
select
2025-12-03
09:00:00
U.S. Stock Futures Rise as Markets Anticipate Fed Rate Cut
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Globenewswire
PinnedPharvaris' Deucrictibant Significantly Reduces HAE Symptom Relief Time
  • Significant Efficacy: Deucrictibant achieved a median time to symptom relief of 1.28 hours in clinical trials, significantly faster than the placebo's over 12 hours (p<0.0001), indicating its potential value in acute HAE attacks.
  • Comprehensive Endpoint Achievement: All 11 secondary efficacy endpoints reached statistical significance, with a median time to complete symptom resolution of 11.95 hours compared to over 24 hours for placebo, showcasing Deucrictibant's rapid action mechanism.
  • Good Safety Profile: Deucrictibant showed no treatment-related serious adverse events during the trial, with 93.2% of patients requiring only a single dose for treatment within 12 hours, indicating its excellent tolerability in clinical use.
  • Broad Market Potential: Pharvaris plans to submit a New Drug Application (NDA) to the FDA in the first half of 2026, which, if approved, will provide the first oral on-demand treatment option for HAE patients, addressing the urgent market need for effective and convenient therapies.
[object Object]
Preview
9.0
12-03NASDAQ.COM
PinnedPharvaris' Phase 3 Study of Deucrictibant for On-Demand HAE Attack Treatment Achieves Important Milestones

  • Positive Phase 3 Trial Results: Pharvaris' shares rose nearly 7% after the RAPIDe-3 trial showed that Deucrictibant significantly reduced symptom relief time for hereditary angioedema (HAE) patients, achieving all primary and secondary endpoints.

  • Efficacy and Safety Profile: Deucrictibant demonstrated rapid efficacy, with 83% of attacks treated with a single capsule and no serious adverse events reported, indicating a favorable safety profile.

  • Future Plans for Approval: Pharvaris intends to submit a New Drug Application to the U.S. FDA for Deucrictibant in the first half of 2026, aiming to provide an effective oral therapy for acute HAE attacks.

  • Ongoing Studies: The company is also conducting an open-label extension study and a Phase 3 study for prophylactic use, with topline data expected in late 2026, potentially making Deucrictibant the first oral therapy for both on-demand and preventive treatment of HAE.

[object Object]
Preview
4.5
12-04NASDAQ.COM
Stocks Rise on Hope for Fed Rate Cuts

  • Market Performance: The S&P 500, Dow Jones, and Nasdaq 100 all closed higher on Wednesday, with the S&P 500 and Nasdaq reaching three-week highs, supported by a weaker-than-expected ADP employment report that lowered bond yields and increased expectations for a Fed interest rate cut.

  • Sector Highlights: Chipmakers saw significant gains, with Microchip Technology rising over 12% after a strong earnings forecast, while other tech stocks also performed well. Conversely, concerns over AI demand affected Microsoft, which saw a decline in stock price.

  • Economic Indicators: The November ADP employment report indicated an unexpected job loss of 32,000, the largest drop in over 2.5 years, while the ISM services index showed unexpected growth, suggesting mixed signals in the labor market and economic activity.

  • Upcoming Economic Focus: Market attention is on upcoming economic reports, including unemployment claims and personal spending, with a high probability of a 25 basis point rate cut anticipated at the next FOMC meeting on December 9-10.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pharvaris NV (PHVS) stock price today?

The current price of PHVS is 27.69 USD — it has decreased -5.7 % in the last trading day.

arrow icon

What is Pharvaris NV (PHVS)'s business?

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

arrow icon

What is the price predicton of PHVS Stock?

Wall Street analysts forecast PHVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHVS is 36.86 USD with a low forecast of 27.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pharvaris NV (PHVS)'s revenue for the last quarter?

Pharvaris NV revenue for the last quarter amounts to -39.66M USD, increased 4.65 % YoY.

arrow icon

What is Pharvaris NV (PHVS)'s earnings per share (EPS) for the last quarter?

Pharvaris NV. EPS for the last quarter amounts to -30687627.00 USD, decreased -8.58 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pharvaris NV (PHVS)'s fundamentals?

The market is revising No Change the revenue expectations for PHVS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 20.13%.
arrow icon

How many employees does Pharvaris NV (PHVS). have?

Pharvaris NV (PHVS) has 82 emplpoyees as of December 05 2025.

arrow icon

What is Pharvaris NV (PHVS) market cap?

Today PHVS has the market capitalization of 1.80B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free